

## **Equity Research**

research@armsecurities.com.ng +234 1 270 1652

8 September 2017

(BUY: №1.34)

## FCMB Group Plc. | Company Note

## FCMB Plc: A forgotten star?

Following a dramatic share price decline (-23% from the year-peak of  $\ge$ 1.42), FCMB now looks attractively valued among our Tier 2 coverage and thus offers legroom for tactical play. The bank trades at a P/B of 0.1x compared to peer average of 0.8x and its FY 17E P/E of 1.8x is at a sizable discount to peer average of 3.9x and its current P/E of 7.6x. Furthermore, at current pricing, its 2017E dividend translates to dividend yield of 10.5%. While we believe higher funding cost and a relatively illiquid balance sheet are valid reasons why FCMB's earnings should struggle, we believe the market has over punished the stock relative to Tier II peers which have rallied 30% YTD. Ahead of Q3 17 results, we think current pricing offers a window for tactical plays and rate the stock a BUY with FVE of ¥1.34 (25% upside from current pricing) with a view that fundamentals will improve through H2 2017.

## High base effect casts H1 17 result in poor light

H1 17 results illuminates two key reasons why investors have been lukewarm towards the stock of FCMB. First, EPS of N0.15 is down 81% YoY largely on the back of a weighty decline in non-interest income (-50% YoY). In addition to this, the bank faced sizable funding cost pressure (interest expense: +24% YoY) in the review period.

Income Statemen	t Data		
	2017 -	2016 -	%chg
	6M'm	6M'm	0
Gross Earnings	77,508	88,283	-12.2%
PBT	3,716	16,289	-77.2%
PAT	2,911	15,668	-81.4%
EPS	0.15	0.79	-81.4%
Balance Sheet Da	ata		
	2017- 6M	2016 -Dec 'm	%chg
	'm		0
Loans	649,199	657,021	-1.2%
Total Assets	1,177,322	1,286,546	-8.5%
Deposits	633,477	689,345	-8.1%
Total liabilities	996,920	1,108,947	-10.1%
Net Assets	180,402	177,599	1.6%
BVPS	9.11	8.97	1.6%
Stock Data			
Price			<del>N</del> 1.0
		210	

Price	<del>N</del> 1.07
52-week range	₩0.90- ₩1.42
Market Cap. (N'Bn)	21.19
1-month Avg. Vol	5,988,962
Curr. PE	7.6x
Bloomberg Ticker	FCMB:NL

FCMB Plc- Share Price Trend



kayode.omosebi@arm.com.ng

On the former, despite an over three-fold expansion in trading income, lower FX gains (-97% YoY) dampened non-interest income.<sup>1</sup> Adjusted for FX gains, H1 17 non-funded revenues are 83% higher YoY.

 Elsewhere, as a Tier II bank, FCMB buckled under the weight of monetary tightening with WACF rising 45bps to 6.7% due to high term-deposit (+2pps YoY to 32% of total deposit) as well as higher interbank lending. Interestingly, this was synonymous across our Tier II coverage.

#### Liquidity bolstering and better asset quality to spur earnings

- In our discussion with FCMB, management revealed plans to address balance sheet inflexibility by focusing asset creation on its investment securities portfolio to harvest the current high yields on government treasury bills. Furthermore, FCMB expects a CRR refund of ~₩23billion in H2 2017, which would improve its balance sheet and earnings capacity. Consequently, despite lingering pressures from funding (FY 17E WACF: +50bps YoY to 6.6%), we expect NIMs to remain flat as with H1 17. The foregoing brings FY 17E interest expense to №61.9billion (+11.3% YoY). Laying our funding cost assumption with FY 17E asset yield of 11.9% (interest income: 8.9% YoY to №136.3billion), we now expect NIM to come in at 6.5% (+30bps YoY). In our view, we expect an improved liquidity picture for FCMB over the rest of the year given reduction in loan as well as potential inflow from CRR refund.
- On NIR, we expect improving FX market activity to drive an expansion in trading income (+18% YoY) while card revenues should recover as banks raise limits on international card usage which should buoy net fee income (+14% YoY) in our view. However, largely reflecting the softer NGN depreciation relative to 2017, we expect weighty decline in other income (-61% YoY)—a reflection of lower FX gains— to keep NIR lower at ¥33.2billion for FY 17E (-30.5% YoY).
- In line with the rest of the sector, net loans declined (-1% QoQ) in line with concerns over conserving capital, a cautious approach towards loan origination and ongoing work-out of its loan book. Given, adequate provisioning over 2016 and H1 17, alongside improvement in the economic environment, we see scope for lower

<sup>&</sup>lt;sup>1</sup> H1 16 NIR was buoyed by NGN depreciation which drove ¥18.3billion in FX gains over the period.

provisioning in FY 17E. Importantly, higher coverage is driven by adequate coverage ratio for non-performing loans as well as challenged sectors (O&G, Power, Commerce, and Individual). Consequently, we forecast coverage ratio of 100% (excl. regulatory reserve) and cost of risk of 3.5% (management guidance: 3%) which results in a 30% YoY decline in loan loss charges to  $\Re$ 24.9billion in FY 17E.

#### Sustained recovery to drive decent FY 17E

• Therefore, with a focus on capturing higher yields on the naira curve, no plans to grow risky assets, lower loan-loss provisioning, increased prospects of recoveries, operational efficiency, and adequate capital buffer, downside risk to 2017 earnings now seems moderated than was earlier expected. Overall, we forecast 2017E EPS of N0.55 (-22% YoY) and DPS of N0.11. However, excluding FX gains in prior year, FY 17 EPS should be four-fold higher YoY. Our FVE of N1.34 posit a 25% upside from current pricing. Consequently, we rate the stock a **BUY**, reflecting attractive valuation and a view that fundamentals will improve through H2 2017 and beyond despite period of lumpiness. Furthermore, across the Tier 2 space, FCMB remains a more resilient bank (save for Stanbic) with key metrics printing above peer average.

# Summary of Results and Forecasts - Naira $(\mathbb{N})$

FY 2015A	FY 2016A	FY 2017F	FY 2018F	FY 2019F
152,508	176,352	169,447	173,098	185,391
123,584	125,109	136,276	138,331	148,450
(59,647)	(55,576)	(61,873)	(54,955)	(58,341)
63,937	69,534	74,403	83,377	90,110
25,760	47,741	33,171	34,767	36,941
(66,979)	(65,774)	(69,872)	(72,585)	(75,885)
(15,033)	(35,522)	(24,960)	(20,647)	(19,854)
7,769	15,979	12,742	24,911	31,312
(3,008)	(1,913)	(1,784)	(3,737)	(5,010)
4,761	14,066	10,958	21,174	26,302
306,474	247,566	259,890	270,286	286,503
592,957	659,937	687,610	729,591	784,728
29,971	32,283	32,187	34,641	37,464
187,088	187,549	207,990	214,230	224,942
1,159,534	1,163,624	1,249,713	1,322,439	1,417,607
	· · ·			
700,217	657,610	739,884	797,255	868,810
196,906	228,793	215,120	221,574	228,221
90,993	79,778	79,778	79,778	79,778
997,143	993,908	1,038,584	1,102,434	1,180,664
162,391	169,716	211,128	220,004	236,944
EV 2015A	EV 2016A	EV 2017E	EV 2019E	FY 2019F
				1.33
	-			0.40
	8 57			11.97
				11.8%
				5.5%
				11.5%
				1.9%
				5.98
/ 14			0.01	5.70
			91 5%	90.3%
84.7%	100.4%	92.9%	91.5% 61.4%	90.3% 59.7%
84.7% 74.7%	100.4% 56.1%	92.9% 65.0%	61.4%	59.7%
84.7%	100.4%	92.9%		
	152,508 123,584 (59,647) 63,937 25,760 (66,979) (15,033) 7,769 (3,008) 4,761 306,474 592,957 29,971 187,088 1,159,534 700,217 196,906 90,993 997,143 162,391 FY 2015A 0.24 0.10 8.20 11.3% 6.7% 3.0% 0.4%	152,508  176,352    123,584  125,109    (59,647)  (55,576)    63,937  69,534    25,760  47,741    (66,979)  (65,774)    (15,033)  (35,522)    7,769  15,979    (3,008)  (1,913)    4,761  14,066    306,474  247,566    592,957  659,937    29,971  32,283    187,088  187,549    1,159,534  1,163,624    700,217  657,610    196,906  228,793    90,993  79,778    997,143  993,908    162,391  169,716    FY 2015A  FY 2016A    0.24  0.71    0.10  -    8.20  8.57    11.3%  11.5%    6.7%  6.1%    3.0%  8.5%	152,508  176,352  169,447    123,584  125,109  136,276    (59,647)  (55,576)  (61,873)    63,937  69,534  74,403    25,760  47,741  33,171    (66,979)  (65,774)  (69,872)    (15,033)  (35,522)  (24,960)    7,769  15,979  12,742    (3,008)  (1,913)  (1,784)    4,761  14,066  10,958	152,508  176,352  169,447  173,098    123,584  125,109  136,276  138,331    (59,647)  (55,576)  (61,873)  (54,955)    63,937  69,534  74,403  83,377    25,760  47,741  33,171  34,767    (66,979)  (65,774)  (69,872)  (72,585)    (15,033)  (35,522)  (24,960)  (20,647)    7,769  15,979  12,742  24,911    (3,008)  (1,913)  (1,784)  (3,737)    4,761  14,066  10,958  21,174    306,474  247,566  259,890  270,286    592,957  659,937  687,610  729,591    29,971  32,283  32,187  34,641    187,088  187,549  207,990  214,230    1,159,534  1,163,624  1,249,713  1,322,439    700,217  657,610  739,884  797,255    196,906  228,793  215,120  221,574    90

Source: ARM Research \*unless otherwise stated

#### **ARM ratings and recommendations**

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

ТОР 20		NON-TOP 20	
Rating	Deviation	Rating	Deviation
STRONG BUY	>20%	BUY	>20%
OVERWEIGHT	10% - 20 %	NEUTRAL	5% - 20%
NEUTRAL	0% - 10%	SELL	<5%
UNDERWEIGHT	-5% - 0%		
SELL	<-5%		

<b>RECOMMENDATION KEY</b>		
Rating	Recommendation	
BUY	Accumulate security to a substantial extent constrained only by portfolio diversification considerations	
OVERWEIGHT	Accumulate security to an extent moderated by cognizance of its benchmark weight	
NEUTRAL	Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reasonable portfolio constraints	
UNDERWEIGHT	Minimise exposure to security taking cognizance of its index weighting	
SELL	Sell-off security completely from portfolio	

Copyright © 2017 ARM Securities Limited ("ARM").

All rights reserved. Unauthorised use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARM and its analysts believe to be reliable. Neither ARM nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARM, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.